


RECEIVED

MAY 08 2002

TECH CENTER 1600/2900



#12/B  
5/14/02  
PATENT  
ATTORNEY DOCKET  
NO. 69176  
Style

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Biedermann et al.

Serial No.: 09/596,001

Filed: June 16, 2000

Title: NEW PIPERAZINYL-  
SUBSTITUTED  
PYRIDYLALKANE, ALKENE AND  
ALKINE CARBOXAMIDES

Group Art Unit: 1624

Examiner: T. Truong

CERTIFICATE OF MAILING

I hereby certify that this  
paper is being deposited with  
the United States Postal  
Service with sufficient  
postage as first class mail  
in an envelope addressed to:  
Commissioner of Patents and  
Trademarks, Washington, D.C.  
20231, on this date.

MAY 01 2002

Date James P. Krueger  
Registration No. 35,234  
Attorney for  
Applicant(s)

Amendment A

Honorable Commissioner of Patents  
and Trademarks  
ATTENTION: Assistant Commissioner  
for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the office action dated November 1, 2001,  
please amend the above-identified application as follows.

IN THE CLAIMS:

Please cancel claims 1, 9-11, 13, 15-23, and 25-31.

2. (Once amended) ~~Pyridylalkane~~, pyridylalkene and  
pyridylalkine carboxamides of formula (I)

B1  
2001  
05/08/2002 HH0HAMH1 00000027 061135 09596001

01 FC:102 840.00 CH

from phenyl, pyridyl or naphthyl,

~~B5F~~  
G<sup>5</sup> is -COR<sup>16</sup>

Sub  
E7 R<sup>16</sup> is selected from the group consisting of  
trifluoromethyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>3</sub>-C<sub>6</sub>-alkenyloxy, and benzyloxy.

---

50. The pharmaceutical composition according to claim 12, wherein the pharmaceutical composition is present in a solid, peroral administrable form as a tablet, capsule, coated tablet, or as a liquid, peroral administration solution, suspension, effervescent tablet, in the form of tabs or sachets, which may be in the form of a suitable injection or infusion preparation together with suitable pharmaceutically acceptable carriers and adjuvants, in the form of a concentrate, powder or lyophilisate, in the form of a gastrointestinal therapeutic system (GITS) for systemic treatment, in the form of a salve, suspension, emulsion, a balm or plaster or in the form of an externally applicable solution, in the form of a rectal, genital, or transurethral administration emulsion, a solution, a liposomal solution, an implant, suppository or a capsule, or in the form of a composition capable of being applied nasally.

---

#### REMARKS

Upon entry of the present amendment, claims 2-8, 12, 14, and 24 have been amended, claims 1, 9-11, 13, 15-23, and 25-31 have been canceled, claims 32-50 have been added, and claims 2-8, 12, 14, 24, and 32-50 are pending. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made".